JPM vs NAD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
NAD demonstrates strong operational health with a Piotroski F-Score of 7/9, yet it trades at a significant premium to its Graham Number ($8.78) and Intrinsic Value ($8.26). While the Price-to-Book ratio of 0.95 suggests the fund is priced reasonably relative to its net asset value, the payout ratio of 318.21% is a critical red flag indicating that dividends are not supported by current earnings. Technical trends are currently bearish (0/100), which offsets the positive 1-year price performance. The fund remains a viable income vehicle but lacks the valuation support for a bullish growth rating.
Compare Another Pair
Related Comparisons
JPM vs NAD: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Nuveen Quality Municipal Income Fund (NAD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.